Cancer Management and Research · 2021 · 13 citations · 23 references
MedicineOncologySurgeryBreast OncologyMetastasisSurgical OncologyBreast Cancer SurgeryBreast PathologyBreast SurgeryHer2-positive Breast CancerBreast Cancer HistopathologyBreast Cancer PrognosisDisease-free Survival AnalysisDisease-free Survival AssessmentHer2 ExpressionLymph Node Metastasis PrognosisMalignant Breast TumorsYoung Women
OBJECTIVE: Breast cancer (BC) in young women tends to be more aggressive. This study highlights the clinicopathological features and outcomes of young breast cancer (YBC) patients in a developing country. METHODS: Consecutive patients aged 35 years or younger with a pathologically confirmed diagnosis of breast cancer treated and followed up at our department were included. Medical records and follow-up databases were reviewed and documented. RESULTS: The rate of breast conservation and reconstruction surgery is higher in YBC patients. YBC patients are more likely to have tumors over 5cm, high-grade, hormone receptor negative, triple negative and stage III than old patients. There was no statistically significant difference in the pathological type, lymph node metastasis, and HER2 status. The median follow-up time was 96 months. The disease-free survival (DFS) was significantly worse in the YBC group. However, the overall survival (OS) had no difference between the two groups. CONCLUSION: YBC patients had more aggressive pathological features, such as hormone receptor negative, triple negative, high-grade and advanced stage, and poorer DFS than the old counterparts.
23
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
K. David Voduc, Maggie C.U. Cheang, Scott Tyldesley et al. · Journal of Clinical Oncology · 2010 · 1.2K citations
Medicine, Cancer Biology, Oncology +14
Evandro de Azambuja, Andrew Holmes, Martine Piccart et al. · The Lancet Oncology · 2014 · 455 citations
Medicine, Oncology, Pharmacology +15